Oppenheimer Maintains Outperform on RxSight, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on RxSight (NASDAQ:RXST) and raises the price target from $61 to $72.
May 07, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on RxSight and raises the price target from $61 to $72.
The increase in price target by a reputable analyst like Steven Lichtman suggests a strong bullish outlook on RxSight, likely leading to positive investor sentiment and a potential increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100